Frank S Lieberman1, Meihua Wang2, H Ian Robins3, Christina I Tsien4, Walter J Curran5, Maria Werner-Wasik6, Ryan P Smith7, Christopher Schultz8, Alan C Hartford9, Peixin Zhang10, Minesh P Mehta11. 1. University of Pittsburgh Medical Center, University of Pittsburgh Physicians, Department of Neurology, Department of Medicine, Pittsburgh, Pennsylvania. Electronic address: liebermanf@upmc.edu. 2. Merck & Co, Kenilworth, New Jersey. 3. University of Wisconsin, Madison, Wisconsin. 4. Washington University School of Medicine, St Louis, Missouri. 5. Emory University, Atlanta, Georgia. 6. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 7. University of Pittsburgh UPMC Shadyside, Pittsburgh, Pennsylvania. 8. Medical College of Wisconsin, Milwaukee, Wisconsin. 9. Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 10. NRG Oncology Statistics and Data Management Center-American College of Radiology, Philadelphia, Pennsylvania. 11. University of Maryland Medical Systems, Baltimore, Maryland.
Abstract
PURPOSE: To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM). METHODS AND MATERIALS: Trial RTOG 04-20, a single-arm, multi-institutional phase 2 trial, was designed to determine the efficacy and toxicity of concomitant TMZ and radiation therapy (RT) followed by adjuvant TMZ combined with CPT-11 given for 12 cycles compared with historical controls of adjuvant TMZ alone given for 6 cycles. RESULTS: A total of 170 patients were enrolled, 152 of whom were eligible. Adjuvant CPT-11 combined with TMZ was more toxic than expected. A higher rate of hematologic and gastrointestinal toxicities was more frequently noted with the combination regimen compared with adjuvant TMZ alone. Grade 3/4 hematologic toxicity was 38% compared with 14% reported in the Stupp trial. After an early interim analysis, the adjuvant CPT-11 dose was reduced to 100 mg/m2 on days 1 and 5 for the first cycle. CPT-11 dose escalation proceeded over the first 3 cycles if tolerated. Median overall survival for all eligible patients was 16.9 months compared with 13.7 months of the historical control (P = .03). Post hoc subgroup analysis suggested an improvement in overall survival for patients with Radiation Therapy Oncology Group recursive partitioning analysis class 3, although improvement was limited to 22 patients (14% of eligible patients). CONCLUSIONS: Although irinotecan and TMZ for 12 cycles given after chemoradiation for patients with newly diagnosed glioblastoma significantly improved median survival compared with historical control data at the time the study was conducted, the historical control median survival time of 13.7 months does not represent the current benchmark for this patient population. Treatment intensification does prolong overall survival compared with the current standard.
PURPOSE: To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM). METHODS AND MATERIALS: Trial RTOG 04-20, a single-arm, multi-institutional phase 2 trial, was designed to determine the efficacy and toxicity of concomitant TMZ and radiation therapy (RT) followed by adjuvant TMZ combined with CPT-11 given for 12 cycles compared with historical controls of adjuvant TMZ alone given for 6 cycles. RESULTS: A total of 170 patients were enrolled, 152 of whom were eligible. Adjuvant CPT-11 combined with TMZ was more toxic than expected. A higher rate of hematologic and gastrointestinal toxicities was more frequently noted with the combination regimen compared with adjuvant TMZ alone. Grade 3/4 hematologic toxicity was 38% compared with 14% reported in the Stupp trial. After an early interim analysis, the adjuvant CPT-11 dose was reduced to 100 mg/m2 on days 1 and 5 for the first cycle. CPT-11 dose escalation proceeded over the first 3 cycles if tolerated. Median overall survival for all eligible patients was 16.9 months compared with 13.7 months of the historical control (P = .03). Post hoc subgroup analysis suggested an improvement in overall survival for patients with Radiation Therapy Oncology Group recursive partitioning analysis class 3, although improvement was limited to 22 patients (14% of eligible patients). CONCLUSIONS: Although irinotecan and TMZ for 12 cycles given after chemoradiation for patients with newly diagnosed glioblastoma significantly improved median survival compared with historical control data at the time the study was conducted, the historical control median survival time of 13.7 months does not represent the current benchmark for this patient population. Treatment intensification does prolong overall survival compared with the current standard.
Authors: V J Patel; G B Elion; P J Houghton; S Keir; A E Pegg; S P Johnson; M E Dolan; D D Bigner; H S Friedman Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: P J Houghton; C F Stewart; P J Cheshire; L B Richmond; M N Kirstein; C A Poquette; M Tan; H S Friedman; T P Brent Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: James J Vredenburgh; Annick Desjardins; David A Reardon; Katherine B Peters; James E Herndon; Jennifer Marcello; John P Kirkpatrick; John H Sampson; Leighann Bailey; Stevie Threatt; Allan H Friedman; Darell D Bigner; Henry S Friedman Journal: Clin Cancer Res Date: 2011-04-29 Impact factor: 12.531
Authors: Michael D Prados; W K A Yung; Kurt A Jaeckle; H Ian Robins; Minesh P Mehta; Howard A Fine; Patrick Y Wen; Timothy F Cloughesy; Susan M Chang; M Kelly Nicholas; David Schiff; Harry S Greenberg; Larry Junck; Karen L Fink; Kenneth R Hess; John Kuhn Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: B Chauffert; L Feuvret; F Bonnetain; L Taillandier; D Frappaz; H Taillia; R Schott; J Honnorat; M Fabbro; I Tennevet; F Ghiringhelli; J S Guillamo; X Durando; D Castera; M Frenay; C Campello; C Dalban; J Skrzypski; O Chinot Journal: Ann Oncol Date: 2014-04-09 Impact factor: 32.976
Authors: Rakesh K Jain; Emmanuelle di Tomaso; Dan G Duda; Jay S Loeffler; A Gregory Sorensen; Tracy T Batchelor Journal: Nat Rev Neurosci Date: 2007-08 Impact factor: 34.870
Authors: Monica E Loghin; Michael D Prados; Patrick Wen; Larry Junck; Frank Lieberman; Howard Fine; Karen L Fink; Minesh Metha; John Kuhn; Kathleen Lamborn; Susan M Chang; Timothy Cloughesy; Lisa M DeAngelis; Ian H Robins; Kenneth D Aldape; W K Alfred Yung Journal: Clin Cancer Res Date: 2007-12-01 Impact factor: 12.531
Authors: Orkhan Mammadov; Burak Han Akkurt; Manfred Musigmann; Asena Petek Ari; David A Blömer; Dilek N G Kasap; Dylan J H A Henssen; Nabila Gala Nacul; Elisabeth Sartoretti; Thomas Sartoretti; Philipp Backhaus; Christian Thomas; Walter Stummer; Walter Heindel; Manoj Mannil Journal: Heliyon Date: 2022-08-02